Guidelines for diagnosis and treatment of Chinese medicine on idiopathic pulmonary fibrosis_Chinese Journal of Evidence-Based Medicine

Authors：

 Internal Medicine Committee of World Federation of Chinese Medicine Societies

Corresponding?author：

Internal Medicine Committee of World Federation of Chinese Medicine Societies, Email: li_js8@163.com

Keywords：

Idiopathic pulmonary fibrosis; Traditional Chinese medicine; Clinical practice guideline

DOI：

10.7507/1672-2531.202407161

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic and interstitial lung disease of unknown cause. It has a serious impact on people's health. Traditional Chinese medicine (TCM) has certain advantages in diagnosing and treating on IPF, which have been widely used in clinic. In order to improve the diagnostic and treatment level for IPF with TCM. The Internal Medicine Committee of World Federation of Chinese Medicine Societies organized and established a multidisciplinary background working group. The document was formulated by referring to the formulation method and process of clinical practice guidelines, which are based on the best evidence and the opinions of clinical physicians and patients. Physicians can use this guideline to make clinical decisions.

Citation： Internal Medicine Committee of World Federation of Chinese Medicine Societies. Guidelines for diagnosis and treatment of Chinese medicine on idiopathic pulmonary fibrosis. Chinese Journal of Evidence-Based Medicine, 2025, 25(3): 249-255. doi: 10.7507/1672-2531.202407161 Copy

1.	Maher TM, Bendstrup E, Dron L, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res, 2021, 22(1): 197.
2.	Cox IA, Otahal P, de Graaff B, et al. Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia. Respirology, 2022, 27(3): 209-216.
3.	Strongman H, Kausar I, Maher TM. Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv Ther, 2018, 35(5): 724-736.
4.	Cottin V, Spagnolo P, Bonniaud P, et al. Mortality and respiratory-related hospitalizations in idiopathic pulmonary fibrosis not treated with antifibrotics. Front Med (Lausanne), 2021, 8: 802989.
5.	Gao J, Kalafatis D, Carlson L, et al. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respir Res, 2021, 22(1): 40.
6.	Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med, 2018, 198(5): e44-e68.
7.	Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med, 2022, 205(9): e18-e47.
8.	Dove EP, Olson AL, Glassberg MK. Trends in idiopathic pulmonary fibrosis-related mortality in the United States: 2000-2017. Am J Respir Crit Care Med, 2019, 200(7): 929-931.
9.	Hopkins RB, Burke N, Fell C, et al. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J, 2016, 48(1): 187-195.
10.	Raimundo K, Chang E, Broder MS, et al. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med, 2016, 16: 2.
11.	Collard HR, Chen SY, Yeh WS, et al. Health care utilization and costs of idiopathic pulmonary fibrosis in U. S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc, 2015, 12(7): 981-987.
12.	宣建偉, 盧永吉, 任懋東, 等. 中國特發性肺纖維化患者的直接經濟負擔. 中國藥物經濟學, 2019, 14(6): 9-12.
13.	Li J, Yu XQ, Xie Y, et al. Efficacy and safety of traditional Chinese medicine treatment for idiopathic pulmonary fibrosis: an exploratory, randomized, double-blinded and placebo controlled trial. Front Pharmacol, 2022, 13: 1053356.
14.	中華中醫藥學會內科分會, 中國民族醫藥學會肺病分會, 中華中醫藥學會肺系病分會. 特發性肺纖維化中醫證候診斷標準(2019版). 中醫雜志, 2020, 61(18): 1653-1656.
15.	張立山, 戴雁彥, 任傳云. 武維屏教授治療肺纖維化十法. 中國中醫藥信息雜志, 2008, 15(4): 94-95.
16.	鞠錚嶸. 肺痿理論—晁恩祥名老中醫治療肺纖維化經驗總結. 北京: 北京中醫藥大學, 2014.
17.	李建生. 特發性肺纖維化中醫辨證治療概要. 中醫學報, 2017, 32(6): 929-931.
18.	徐慧卿. 針藥并用治療特發性肺纖維化療效觀察. 上海針灸雜志, 2010, 29(10): 641-642.
19.	李戎, 閆智勇, 李文軍, 等. 針灸治療特發性肺纖維化臨床觀察. 針灸臨床雜志, 2004, (2): 13-14,59.
20.	王艷, 謝洋, 吉紫樂, 等. 中藥離子導入輔助治療特發性肺纖維化療效與安全性的Meta分析. 中醫學報, 2023, 38(3): 665-672.
21.	白文梅, 馬紅霞, 同立宏. 益氣活血通絡膏方治療氣虛血瘀型特發性肺纖維化60例療效觀察. 新疆中醫藥, 2018, 36(6): 7-8.
22.	楊柳, 成淑芳, 張樹森, 等. 康益膏方治療特發性肺纖維化60例. 光明中醫, 2015, 30(7): 1449-1450.
23.	張樹森, 楊柳, 董瑞. 珠及膏治療特發性肺纖維化氣陰兩傷型臨床觀察. 中國中醫藥現代遠程教育, 2019, 17(23): 69-71.
24.	劉香玉, 李怡良, 戈艷蕾, 等. 隔姜督灸聯合陽和湯化裁治療特發性肺間質纖維化臨床觀察. 云南中醫中藥雜志, 2021, 42(5): 31-34.
25.	周劍, 吳炳辰. 熱敏灸聯合藥物對肺腎氣虛型特發性肺纖維化患者肺功能及血清FGF-21、MMP-7的影響. 上海針灸雜志, 2021, 40(2): 152-156.
26.	李彬, 張一, 楊秦梅. 臍灸治療肺脾氣虛型特發性肺間質纖維化合并胃食管反流療效觀察. 中國針灸, 2019, 39(3): 241-245.

1. Maher TM, Bendstrup E, Dron L, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res, 2021, 22(1): 197.
2. Cox IA, Otahal P, de Graaff B, et al. Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia. Respirology, 2022, 27(3): 209-216.
3. Strongman H, Kausar I, Maher TM. Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv Ther, 2018, 35(5): 724-736.
4. Cottin V, Spagnolo P, Bonniaud P, et al. Mortality and respiratory-related hospitalizations in idiopathic pulmonary fibrosis not treated with antifibrotics. Front Med (Lausanne), 2021, 8: 802989.
5. Gao J, Kalafatis D, Carlson L, et al. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respir Res, 2021, 22(1): 40.
6. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med, 2018, 198(5): e44-e68.
7. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med, 2022, 205(9): e18-e47.
8. Dove EP, Olson AL, Glassberg MK. Trends in idiopathic pulmonary fibrosis-related mortality in the United States: 2000-2017. Am J Respir Crit Care Med, 2019, 200(7): 929-931.
9. Hopkins RB, Burke N, Fell C, et al. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J, 2016, 48(1): 187-195.
10. Raimundo K, Chang E, Broder MS, et al. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med, 2016, 16: 2.
11. Collard HR, Chen SY, Yeh WS, et al. Health care utilization and costs of idiopathic pulmonary fibrosis in U. S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc, 2015, 12(7): 981-987.
12. 宣建偉, 盧永吉, 任懋東, 等. 中國特發性肺纖維化患者的直接經濟負擔. 中國藥物經濟學, 2019, 14(6): 9-12.
13. Li J, Yu XQ, Xie Y, et al. Efficacy and safety of traditional Chinese medicine treatment for idiopathic pulmonary fibrosis: an exploratory, randomized, double-blinded and placebo controlled trial. Front Pharmacol, 2022, 13: 1053356.
14. 中華中醫藥學會內科分會, 中國民族醫藥學會肺病分會, 中華中醫藥學會肺系病分會. 特發性肺纖維化中醫證候診斷標準(2019版). 中醫雜志, 2020, 61(18): 1653-1656.
15. 張立山, 戴雁彥, 任傳云. 武維屏教授治療肺纖維化十法. 中國中醫藥信息雜志, 2008, 15(4): 94-95.
16. 鞠錚嶸. 肺痿理論—晁恩祥名老中醫治療肺纖維化經驗總結. 北京: 北京中醫藥大學, 2014.
17. 李建生. 特發性肺纖維化中醫辨證治療概要. 中醫學報, 2017, 32(6): 929-931.
18. 徐慧卿. 針藥并用治療特發性肺纖維化療效觀察. 上海針灸雜志, 2010, 29(10): 641-642.
19. 李戎, 閆智勇, 李文軍, 等. 針灸治療特發性肺纖維化臨床觀察. 針灸臨床雜志, 2004, (2): 13-14,59.
20. 王艷, 謝洋, 吉紫樂, 等. 中藥離子導入輔助治療特發性肺纖維化療效與安全性的Meta分析. 中醫學報, 2023, 38(3): 665-672.
21. 白文梅, 馬紅霞, 同立宏. 益氣活血通絡膏方治療氣虛血瘀型特發性肺纖維化60例療效觀察. 新疆中醫藥, 2018, 36(6): 7-8.
22. 楊柳, 成淑芳, 張樹森, 等. 康益膏方治療特發性肺纖維化60例. 光明中醫, 2015, 30(7): 1449-1450.
23. 張樹森, 楊柳, 董瑞. 珠及膏治療特發性肺纖維化氣陰兩傷型臨床觀察. 中國中醫藥現代遠程教育, 2019, 17(23): 69-71.
24. 劉香玉, 李怡良, 戈艷蕾, 等. 隔姜督灸聯合陽和湯化裁治療特發性肺間質纖維化臨床觀察. 云南中醫中藥雜志, 2021, 42(5): 31-34.
25. 周劍, 吳炳辰. 熱敏灸聯合藥物對肺腎氣虛型特發性肺纖維化患者肺功能及血清FGF-21、MMP-7的影響. 上海針灸雜志, 2021, 40(2): 152-156.
26. 李彬, 張一, 楊秦梅. 臍灸治療肺脾氣虛型特發性肺間質纖維化合并胃食管反流療效觀察. 中國針灸, 2019, 39(3): 241-245.

Next Article
Disease burden of non-COVID-19 lower respiratory infection in China, 1990?2021

Chinese Journal of Evidence-Based Medicine

Guidelines for diagnosis and treatment of Chinese medicine on idiopathic pulmonary fibrosis

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content